United States Pharmaceutical Contract Manufacturing Market Insight
Published: 01 June 2026 | Report Format: Electronic (PDF)
United States pharmaceutical contract manufacturing market is projected to grow at a CAGR of approximately 7.4% from 2025 to 2035, driven by rising biologics production, and expanding investments in advanced drug manufacturing technologies.
U.S. Pharmaceutical Contract Manufacturing Market Insights Forecasts to 2035
- The US Pharmaceutical Contract Manufacturing Market Size Was Estimated at USD 78.6 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 7.4% from 2025 to 2035
- The US Pharmaceutical Contract Manufacturing Market Size is Expected to Reach USD 160.8 Billion by 2035
Notable Insights for U.S. Pharmaceutical Contract Manufacturing Market
- By service type, active pharmaceutical ingredient (API) manufacturing accounted for nearly 34% share of the United States pharmaceutical contract manufacturing market in 2025.
- The United States government and private pharmaceutical sector collectively invested more than USD 42.7 Billion toward drug manufacturing modernization, biologics production facilities, vaccine manufacturing infrastructure, and pharmaceutical supply chain expansion between 2024 and 2026.
- Approximately USD 16.3 Billion was allocated across sterile injectable manufacturing systems, advanced continuous manufacturing technologies, AI-enabled pharmaceutical production platforms, and high-potency API processing facilities nationwide.
Download the eBook (ToC)
- Oncology drug manufacturing represented nearly 29% share of the overall market in 2025 due to rising cancer therapeutics production and increasing investment in precision medicine development nationwide.
Research Methodologies Used to Analyze the United States Pharmaceutical Contract Manufacturing Market
This report regarding the U.S. pharmaceutical contract manufacturing market is based on a combination of both primary and secondary research methodologies. Approximately 72% of the analytical framework is derived from secondary research sources, while nearly 28% is supported through primary interviews conducted with pharmaceutical manufacturers, biologics producers, contract development organizations, API suppliers, healthcare consultants, regulatory experts, biotechnology researchers, and senior industry stakeholders operating throughout the United States healthcare sector. Secondary research sources include FDA compliance reports, NIH healthcare studies, pharmaceutical manufacturing journals, biologics production databases, healthcare investment publications, company annual reports, biotechnology research papers, vaccine manufacturing studies, government healthcare policy documents, and technical publications associated with pharmaceutical production technologies.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors research delivers comprehensive market intelligence through detailed industry analysis, competitive benchmarking, trend forecasting, and data-driven business insights. Our research methodology combines advanced analytical frameworks with extensive primary and secondary research to help organizations make informed and strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the US Pharmaceutical Contract Manufacturing market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United States Pharmaceutical Contract Manufacturing Market
- Catalent Inc.
- Thermo Fisher Scientific Inc.
- Lonza Group AG
- Pfizer CentreOne
- Samsung Biologics
- Recipharm AB
- Boehringer Ingelheim BioXcellence
- PCI Pharma Services
- Others
Recent Developments:
- In March 2026, Thermo Fisher Scientific Inc. expanded biologics manufacturing operations across the United States, improving large-scale drug production capacity by approximately 18%.
- In January 2026, Lonza Group AG invested approximately USD 620 Million toward expansion of cell and gene therapy manufacturing infrastructure supporting next-generation biologics production across the United States.
Market Segmentation:
United States Pharmaceutical Contract Manufacturing Market, By Service Type
- API Manufacturing
- Finished Dosage Form Manufacturing
- Packaging Services
- Biologics Manufacturing
- Sterile Injectable Manufacturing
- Others
United States Pharmaceutical Contract Manufacturing Market, By Application
- Oncology
- Cardiovascular Diseases
- Infectious Diseases
- Neurology
- Respiratory Disorders
- Others
United States Pharmaceutical Contract Manufacturing Market, By End User
- Pharmaceutical Companies
- Biotechnology Companies
- Research Organizations
- Healthcare Institutions
- Others
Expert Views:
The US market for pharmaceutical contract manufacturing will see sustained momentum for the long term, driven mainly by biologics outsourcing growth, developments in precision medicine, and significant investment in pharmaceutical manufacturing facilities in the country.
Author: Komal and Radhika By Spherical Insights and Consulting